(Press-News.org) A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
Led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center, the work builds on prior discoveries at NYU Langone that revealed how pancreatic cancer cells, to avert starvation and keep growing, find alternate fuel sources. Normally supplied by the bloodstream, oxygen, blood sugar, and other resources become scarce as the increasing density of fast-growing pancreatic tumors cuts off their own blood supply. In this environment, the ability to switch fuels contributes to the deadliness of pancreatic cancers.
Published online October 9 in Nature Cancer, the new study involves a drug designed to prevent pancreatic ductal adenocarcinoma (PDAC) cells from one such switch. PDAC cells use the enzyme glutaminase to convert the amino acid glutamate into glutamine, a form that can be burned for fuel to sustain rapid tumor growth. Drugs designed to block glutaminase, however, have been shown to cause cancer cells to switch to still other scavenging pathways.
For this reason, the field next looked at experimental treatments like DRP-104, designed by Dracen Pharmaceuticals, a new “prodrug” form of the compound 6-Diazo-5-oxo-L-norleucine (DON) that is preferentially activated within tumors to overcome toxicity issues seen with DON. DON was designed to starve cancer cells by mimicking glutamine, which unlike glutaminase blockers, broadly inhibits all metabolic pathways that use glutamine. Currently in clinical trials against non-small cell lung cancer, DRP-104 cannot be burned as fuel, but clings to the same enzymes as glutamine.
In the current study, DRP-104 treatment alone decreased PDAC growth in mouse models of pancreatic cancer. Importantly, the current team also found that PDAC cells pushed into metabolic crisis by DRP-104 increase signaling through a protein called extracellular signal-regulated kinase or ERK, to make up for their loss of glutamine metabolism. When the team combined DRP-104 with an existing drug that blocks the ERK signaling pathway, trametinib, it further improved survival in pancreatic cancer mouse models compared to DRP-104 treatment alone.
“Despite a decade of advances in understanding how cancer cells switch fuel sources, we have not yet effectively translated this into clinically relevant therapies,” says corresponding study author Alec Kimmelman, M.D., Ph.D., the Anita Steckler and Joseph Steckler Chair of Radiation Oncology at NYU Langone Health. “Broad antagonism of metabolic pathways with glutamine analogs may provide another mode of attack against these highly resistant tumor cells. The fact that such drugs are already being tested in the clinic makes us hopeful that we may finally see patient outcomes improve, if this approach proves to be effective in clinical trials.”
Moving forward, the research team will seek to understand how glutamine antagonism impacts other adaptive nutrient scavenging mechanisms in pancreatic cancers and whether these could be targeted as well. The success of such approaches will depend on careful balancing of improved therapeutic efficacy and toxicity from the potential effects on normal tissues, Kimmelman adds.
Along with Kimmelman, authors from Perlmutter Cancer Center and the Department of Radiation Oncology at NYU Langone were Joel Encarnación-Rosado, Albert Sohn, Douglas Biancur, Elaine Lin, Victoria Osorio-Vasquez, and Diana González-Baerga. Also Perlmutter authors were Ende Zhao and Diane Simeone. Also authors of the study were Tori Rodrick and Drew Jones from the Division of Advanced Research Technologies at NYU Grossman School of Medicine; Seth Parker from the Department of Biochemistry & Molecular Biology at University of British Columbia in Vancouver, and Yumi Yokoyama and Robert Wild from Dracen Pharmaceuticals, Inc., of San Diego.
Funding for the study came from Perlmutter Cancer Center support grant P30CA016087 and National Cancer Institute grants P01A1080192, P01CA117969, R35CA232124, P30CA016087-38, 1R01CA251726-01A1; as well as from the Lustgarten Foundation, Stand Up to Cancer, and the Howard Hughes Medical Gilliam Fellowships.
Kimmelman has financial interests in Vescor Therapeutics, is on the scientific advisory board of Rafael/Cornerstone Pharmaceuticals and OncoRev, and has been a consultant for Deciphera and Abbvie. These relationships are being managed according with the policies of NYU Langone Health. Yokoyama and Wild are employees of, and have ownership in, Dracen Pharmaceuticals, maker of DRP-104.
END
Newfound mechanism suggests drug combination could starve pancreatic cancer
2023-10-09
ELSE PRESS RELEASES FROM THIS DATE:
Epigenetic regulator MOF drives mitochondrial metabolism
2023-10-09
The intricate control of cellular metabolism relies on the coordinated and harmonious interplay between the nucleus and mitochondria. On the one hand, mitochondria are the hub for the production of essential metabolites, which aside from being required to meet the energy demands of the cell, also serve as the building blocks for constructing both genetic and epigenetic landscapes in the nucleus. On the other hand, the majority of mitochondrial metabolic enzymes are encoded by the nuclear genome, making the function of these two organelles highly interdependent on one another. Inter-organellar communication is aided by molecules that shuttle between these two compartments. ...
Do you know a stroke hero?
2023-10-09
Each year, approximately 800,000 people in the U.S. experience a stroke, according to the American Heart Association’s 2023 Heart Disease and Stroke Statistical Update. Individuals and groups making a difference in the stroke community have a chance to be nationally recognized with a 2024 Stroke Hero Award from the American Stroke Association, a division of the American Heart Association, which is devoted to a world of healthier lives for all.
Stroke is the fifth leading cause of death and a leading cause of serious, long-term ...
UofL receives $16 million to increase supply of primary care physicians for underserved rural and urban areas
2023-10-09
The University of Louisville has received $16 million to help increase Kentuckians’ access to health care, particularly in underserved rural and urban areas. The UofL School of Medicine will use the funds from a four-year grant from the Health Resources and Services Administration (HRSA) to train more primary care physicians and encourage them to practice in underserved communities where they are needed.
Kentucky has a severe shortage of health care providers, with at least some portion of 113 of the state’s 120 counties designated as Health Professional Shortage Areas, including ...
TAVR: Less than one-third of patients enter cardiac rehab after heart procedure
2023-10-09
The vast majority of people who have a minimally invasive heart valve replacement procedure do not participate in recommended cardiac rehabilitation, a Michigan Medicine-led study finds.
Researchers used clinical registry and health care claims data from over 3,300 patients who underwent transcatheter aortic valve replacement, or TAVR, in Michigan across 24 hospitals between 2016 and mid-2020, to determine the rate of cardiac rehabilitation participation and the factors associated with its utilization.
Results published in JACC: Advances reveal that just 30.6% ...
Newly-discovered “margarita snails” from the Florida Keys are bright lemon-yellow
2023-10-09
The “Margaritaville” in Jimmy Buffett’s famous song isn’t a real place, but it’s long been associated with the Florida Keys. This string of tropical islands is home to the only living coral barrier reef in the continental US, along with many animals found nowhere else in the world. One of them is a newly-discovered, bright yellow snail, named in honor of Margaritaville. The lemon- (or, key-lime-) colored snail, along with its lime-green cousin from Belize, is the subject of a study published in the journal PeerJ.
These marine snails are distant relatives of the land-dwelling gastropods you ...
McLean Hospital collaborates with Rippl Care to address urgent mental health needs of seniors living with dementia and their family caregivers
2023-10-09
To address a crisis of unmet mental health needs among seniors with dementia and their family caregivers amid a shortage of mental health providers with expertise treating this population, McLean Hospital, a member of Mass General Brigham, has entered into an agreement to offer strategic advisory services and professional education to Rippl Care. Rippl provides specialty dementia care and is pioneering a new care model in an effort to expand access to high quality, wraparound behavioral healthcare for seniors, their families and caregivers. Under McLean’s agreement with Rippl Care, leaders in the ...
Heart disease risk, prevention and management redefined
2023-10-09
Advisory Highlights:
A new American Heart Association presidential advisory identifies the strong connections among cardiovascular disease (CVD), kidney disease, Type 2 diabetes and obesity, and suggests redefining CVD risk, prevention and management.
The advisory defines cardiovascular-kidney-metabolic (CKM) syndrome for the first time.
CKM syndrome ranges from Stage 0, or no risk factors and an entirely preventive focus, to Stage 4, the highest-risk stage with cardiovascular disease. Stage 4 may also include kidney failure.
The advisory urges use of a new tool that will predict someone’s likelihood of heart attack, stroke and/or heart failure ...
Clinical trial demonstrates benefits of solriamfetol for adults with ADHD
2023-10-09
BOSTON – Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use. A recent clinical trial published in the Journal of Clinical Psychiatry by investigators at Massachusetts General Hospital (MGH), a founding member of Mass General Brigham (MGB), has demonstrated that the drug solriamfetol may be an effective alternative for managing ADHD in adults.
Solriamfetol is currently approved in the United States for ...
Tropical ecosystems more reliant on emerging aquatic insects, study finds, potentially putting them at greater risk
2023-10-09
A team of researchers from Queen Mary University of London and the University of Campinas in Brazil has found that tropical forest ecosystems are more reliant on aquatic insects than temperate forest ecosystems and are therefore more vulnerable to disruptions to the links between land and water.
The study, published in the journal Ecology Letters, is the first to directly compare the interconnections between land and water in tropical and temperate environments via the emergence of aquatic insects. The researchers used a technique called stable isotope analysis to trace ...
Plate tectonic surprise: Utrecht geologist unexpectedly finds remnants of a lost mega-plate
2023-10-09
Utrecht University geologist Suzanna van de Lagemaat has reconstructed a massive and previously unknown tectonic plate that was once one-quarter the size of the Pacific Ocean. Her colleagues in Utrecht had predicted its existence over 10 years ago based on fragments of old tectonic plates found deep in the Earth’s mantle. Van de Lagemaat reconstructed lost plates through field research and detailed investigations of the mountain belts of Japan, Borneo, the Philippines, New Guinea, and New Zealand. To her surprise, she found that oceanic remnants on northern Borneo must have belonged to the long-suspected plate, which scientists have named Pontus. She has now reconstructed ...